Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone

M. Bongiovanni, N. Gianotti, E. Chiesa, P. Nasta, P. Cicconi, A. Capetti, A. Di Biagio, A. Matti, V. Tirelli, P. Marconi, A. De Luca, C. Mussini, F. Gatti, M. Zaccarelli, C. Abeli, C. Torti, A. Antinori, A. Castagna, A. D'Arminio Monforte

Research output: Contribution to journalArticle

Abstract

We evaluated the efficacy of tenofovir (TDF) - and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We included in the study 245 subjects who started a TDF/ddI-containing HAART with HIV-RNA > 3 log10 cp/ml and an available genotypic resistance test at baseline. At baseline, median CD4 counts and HIV-RNA were 278 cell/mmc and 4.32 log 10 cp/ml, respectively. Seventy-four subjects (30.2%) discontinued TDF and/or ddI, 23 of them for drug-related toxicities or intolerance. One-hundred and twenty-six (51.4%) subjects achieved virologic success (HIV-RNA <50 copies/ml in two consecutive determinations) in a median time of 6.1 months; higher HIV-RNA levels (HR: 0.66, 95% CI: 0.54- 0.79, p <0.001 for each additional log10 copies/ml), and the total number of mutations either for PI and NNRTI at baseline (HR: 0.87, 95% CI: 0.81-0.92, p <0.001 for each additional mutation) were both predictors of virologic success. M184V was marginally associated with virologic success (HR: 1.34, 95% CI: 0.94-1.90, p = 0.10 vs no M184V), whilst the number of TAMs was not associated. One-hundred-thirty-three (54.3%) subjects achieved immunologic success (increase of ≥ 100 cells/mm3 from baseline) in a median time of 7.5 months; immunologic success was associated with HIV-RNA levels at baseline (HR: 0.91, 95% CI: 0.79-0.98, p = 0.04 for each additional log10 copies/ml), the total number of mutations either for PI or NNRTI (HR: 0.91, 95% CI: 0.85-0.98, p = 0.01 for each additional mutation) and CD4 count at baseline (HR: 1.11, 95% CI: 1.00-1.23, p = 0.05 for each additional 100 cells/mm3). Results obtained by the on-treatment analyses were comparable. In our study, HAART containing TDF/ddI seem associated with a virologic and immunologic response, when such regimens are chosen according to a genotypic resistance test.

Original languageEnglish
Pages (from-to)451-456
Number of pages6
JournalInfection
Volume35
Issue number6
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Tenofovir
Didanosine
Highly Active Antiretroviral Therapy
Observational Studies
HIV
RNA
Mutation
CD4 Lymphocyte Count
Drug-Related Side Effects and Adverse Reactions

ASJC Scopus subject areas

  • Microbiology (medical)
  • Immunology

Cite this

Bongiovanni, M., Gianotti, N., Chiesa, E., Nasta, P., Cicconi, P., Capetti, A., ... D'Arminio Monforte, A. (2007). Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. Infection, 35(6), 451-456. https://doi.org/10.1007/s15010-007-7120-x

Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. / Bongiovanni, M.; Gianotti, N.; Chiesa, E.; Nasta, P.; Cicconi, P.; Capetti, A.; Di Biagio, A.; Matti, A.; Tirelli, V.; Marconi, P.; De Luca, A.; Mussini, C.; Gatti, F.; Zaccarelli, M.; Abeli, C.; Torti, C.; Antinori, A.; Castagna, A.; D'Arminio Monforte, A.

In: Infection, Vol. 35, No. 6, 12.2007, p. 451-456.

Research output: Contribution to journalArticle

Bongiovanni, M, Gianotti, N, Chiesa, E, Nasta, P, Cicconi, P, Capetti, A, Di Biagio, A, Matti, A, Tirelli, V, Marconi, P, De Luca, A, Mussini, C, Gatti, F, Zaccarelli, M, Abeli, C, Torti, C, Antinori, A, Castagna, A & D'Arminio Monforte, A 2007, 'Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone', Infection, vol. 35, no. 6, pp. 451-456. https://doi.org/10.1007/s15010-007-7120-x
Bongiovanni, M. ; Gianotti, N. ; Chiesa, E. ; Nasta, P. ; Cicconi, P. ; Capetti, A. ; Di Biagio, A. ; Matti, A. ; Tirelli, V. ; Marconi, P. ; De Luca, A. ; Mussini, C. ; Gatti, F. ; Zaccarelli, M. ; Abeli, C. ; Torti, C. ; Antinori, A. ; Castagna, A. ; D'Arminio Monforte, A. / Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone. In: Infection. 2007 ; Vol. 35, No. 6. pp. 451-456.
@article{e678cbe87d784fa89d4b6cbcf54eca35,
title = "Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone",
abstract = "We evaluated the efficacy of tenofovir (TDF) - and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We included in the study 245 subjects who started a TDF/ddI-containing HAART with HIV-RNA > 3 log10 cp/ml and an available genotypic resistance test at baseline. At baseline, median CD4 counts and HIV-RNA were 278 cell/mmc and 4.32 log 10 cp/ml, respectively. Seventy-four subjects (30.2{\%}) discontinued TDF and/or ddI, 23 of them for drug-related toxicities or intolerance. One-hundred and twenty-six (51.4{\%}) subjects achieved virologic success (HIV-RNA <50 copies/ml in two consecutive determinations) in a median time of 6.1 months; higher HIV-RNA levels (HR: 0.66, 95{\%} CI: 0.54- 0.79, p <0.001 for each additional log10 copies/ml), and the total number of mutations either for PI and NNRTI at baseline (HR: 0.87, 95{\%} CI: 0.81-0.92, p <0.001 for each additional mutation) were both predictors of virologic success. M184V was marginally associated with virologic success (HR: 1.34, 95{\%} CI: 0.94-1.90, p = 0.10 vs no M184V), whilst the number of TAMs was not associated. One-hundred-thirty-three (54.3{\%}) subjects achieved immunologic success (increase of ≥ 100 cells/mm3 from baseline) in a median time of 7.5 months; immunologic success was associated with HIV-RNA levels at baseline (HR: 0.91, 95{\%} CI: 0.79-0.98, p = 0.04 for each additional log10 copies/ml), the total number of mutations either for PI or NNRTI (HR: 0.91, 95{\%} CI: 0.85-0.98, p = 0.01 for each additional mutation) and CD4 count at baseline (HR: 1.11, 95{\%} CI: 1.00-1.23, p = 0.05 for each additional 100 cells/mm3). Results obtained by the on-treatment analyses were comparable. In our study, HAART containing TDF/ddI seem associated with a virologic and immunologic response, when such regimens are chosen according to a genotypic resistance test.",
author = "M. Bongiovanni and N. Gianotti and E. Chiesa and P. Nasta and P. Cicconi and A. Capetti and {Di Biagio}, A. and A. Matti and V. Tirelli and P. Marconi and {De Luca}, A. and C. Mussini and F. Gatti and M. Zaccarelli and C. Abeli and C. Torti and A. Antinori and A. Castagna and {D'Arminio Monforte}, A.",
year = "2007",
month = "12",
doi = "10.1007/s15010-007-7120-x",
language = "English",
volume = "35",
pages = "451--456",
journal = "Infection",
issn = "0300-8126",
publisher = "Urban und Vogel GmbH",
number = "6",

}

TY - JOUR

T1 - Observational study on HIV-infected subjects failing HAART receiving tenofovir plus didanosine as NRTI backbone

AU - Bongiovanni, M.

AU - Gianotti, N.

AU - Chiesa, E.

AU - Nasta, P.

AU - Cicconi, P.

AU - Capetti, A.

AU - Di Biagio, A.

AU - Matti, A.

AU - Tirelli, V.

AU - Marconi, P.

AU - De Luca, A.

AU - Mussini, C.

AU - Gatti, F.

AU - Zaccarelli, M.

AU - Abeli, C.

AU - Torti, C.

AU - Antinori, A.

AU - Castagna, A.

AU - D'Arminio Monforte, A.

PY - 2007/12

Y1 - 2007/12

N2 - We evaluated the efficacy of tenofovir (TDF) - and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We included in the study 245 subjects who started a TDF/ddI-containing HAART with HIV-RNA > 3 log10 cp/ml and an available genotypic resistance test at baseline. At baseline, median CD4 counts and HIV-RNA were 278 cell/mmc and 4.32 log 10 cp/ml, respectively. Seventy-four subjects (30.2%) discontinued TDF and/or ddI, 23 of them for drug-related toxicities or intolerance. One-hundred and twenty-six (51.4%) subjects achieved virologic success (HIV-RNA <50 copies/ml in two consecutive determinations) in a median time of 6.1 months; higher HIV-RNA levels (HR: 0.66, 95% CI: 0.54- 0.79, p <0.001 for each additional log10 copies/ml), and the total number of mutations either for PI and NNRTI at baseline (HR: 0.87, 95% CI: 0.81-0.92, p <0.001 for each additional mutation) were both predictors of virologic success. M184V was marginally associated with virologic success (HR: 1.34, 95% CI: 0.94-1.90, p = 0.10 vs no M184V), whilst the number of TAMs was not associated. One-hundred-thirty-three (54.3%) subjects achieved immunologic success (increase of ≥ 100 cells/mm3 from baseline) in a median time of 7.5 months; immunologic success was associated with HIV-RNA levels at baseline (HR: 0.91, 95% CI: 0.79-0.98, p = 0.04 for each additional log10 copies/ml), the total number of mutations either for PI or NNRTI (HR: 0.91, 95% CI: 0.85-0.98, p = 0.01 for each additional mutation) and CD4 count at baseline (HR: 1.11, 95% CI: 1.00-1.23, p = 0.05 for each additional 100 cells/mm3). Results obtained by the on-treatment analyses were comparable. In our study, HAART containing TDF/ddI seem associated with a virologic and immunologic response, when such regimens are chosen according to a genotypic resistance test.

AB - We evaluated the efficacy of tenofovir (TDF) - and didanosine (ddI)-containing backbones in HIV-infected experienced subjects. We included in the study 245 subjects who started a TDF/ddI-containing HAART with HIV-RNA > 3 log10 cp/ml and an available genotypic resistance test at baseline. At baseline, median CD4 counts and HIV-RNA were 278 cell/mmc and 4.32 log 10 cp/ml, respectively. Seventy-four subjects (30.2%) discontinued TDF and/or ddI, 23 of them for drug-related toxicities or intolerance. One-hundred and twenty-six (51.4%) subjects achieved virologic success (HIV-RNA <50 copies/ml in two consecutive determinations) in a median time of 6.1 months; higher HIV-RNA levels (HR: 0.66, 95% CI: 0.54- 0.79, p <0.001 for each additional log10 copies/ml), and the total number of mutations either for PI and NNRTI at baseline (HR: 0.87, 95% CI: 0.81-0.92, p <0.001 for each additional mutation) were both predictors of virologic success. M184V was marginally associated with virologic success (HR: 1.34, 95% CI: 0.94-1.90, p = 0.10 vs no M184V), whilst the number of TAMs was not associated. One-hundred-thirty-three (54.3%) subjects achieved immunologic success (increase of ≥ 100 cells/mm3 from baseline) in a median time of 7.5 months; immunologic success was associated with HIV-RNA levels at baseline (HR: 0.91, 95% CI: 0.79-0.98, p = 0.04 for each additional log10 copies/ml), the total number of mutations either for PI or NNRTI (HR: 0.91, 95% CI: 0.85-0.98, p = 0.01 for each additional mutation) and CD4 count at baseline (HR: 1.11, 95% CI: 1.00-1.23, p = 0.05 for each additional 100 cells/mm3). Results obtained by the on-treatment analyses were comparable. In our study, HAART containing TDF/ddI seem associated with a virologic and immunologic response, when such regimens are chosen according to a genotypic resistance test.

UR - http://www.scopus.com/inward/record.url?scp=37449008495&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37449008495&partnerID=8YFLogxK

U2 - 10.1007/s15010-007-7120-x

DO - 10.1007/s15010-007-7120-x

M3 - Article

C2 - 18034204

AN - SCOPUS:37449008495

VL - 35

SP - 451

EP - 456

JO - Infection

JF - Infection

SN - 0300-8126

IS - 6

ER -